述评(Commentary)

药物涂层球囊治疗周围动脉疾病的循证医学证据

Published at: 2016年第25卷第6期

郭伟 1 , 卫任 1
1 中国人民解放军总医院 血管外科,北京 100853
通讯作者 伟 郭 Email: Pla301dml@vip.sina.com
DOI: 10.3978/j.issn.1005-6947.10.3978/j.issn.1005-6947.2016.06.001
基金:

摘要

药物涂层球囊(DCB)为治疗周围动脉疾病提供了新的策略,国际上已对其有效性开展了诸多对照研究,其中更多集中在对股腘动脉病变的治疗方面。相对于普通球囊,DCB能够减少股腘动脉TASC-A/B级病变术后6个月甚至1年内的晚期管腔缺失和再狭窄率,减少二次干预率,而其中、远期结果,而且在处理TASC-C/D级病变中的效果尚缺少充分的研究报道。关于DCB治疗膝下动脉病变的临床对照研究相对较少,而且与普通球囊的对比结果也并不一致。因此亟待高证据级别的临床随机对照试验来回答这些问题。


Drug-coated balloon for peripheral artery diseases: current evidence-based data

Abstract

Drug-coated balloon (DCB) provides a new treatment strategy for peripheral artery diseases (PAD) and its effectiveness has been tested in several controlled studies in different countries, most of which focused on its use in femoropopliteal leisons. Compared with uncoated balloon, DCB can reduce late lumen loss and restenosis of femoropopliteal TASC-A/B lesions at 6 months and even 1 year after operation and decrease the re-intervention rate, but there is a lack of its mid- and long-term follow-up results as well as its efficacy for TASC-C/D lesions. Studies on using DCB in treatment of infra-popliteal diseases are relatively scarce, in which even more unfortunately, the results are not consistent with each other in terms of comparison between DCB and uncoated balloon. Thus, more high-quality well-controlled studies are urgently needed to answer these questions.


comments powered by Disqus

全文

引用

引用本文: 伟 郭, 任 卫. 药物涂层球囊治疗周围动脉疾病的循证医学证据 [J]. 中国普通外科杂志, 2016, 25(6): 785-789.
Cite this article as: GUO Wei, WEI Ren . Drug-coated balloon for peripheral artery diseases: current evidence-based data[J]. Chin J Gen Surg, 2016, 25(6): 785-789.